These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 15865826

  • 1. The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations.
    Rackham OJ, Thorburn K, Kerr SJ.
    Cardiol Young; 2005 Jun; 15(3):251-5. PubMed ID: 15865826
    [Abstract] [Full Text] [Related]

  • 2. Economic analysis of palivizumab in infants with congenital heart disease.
    Yount LE, Mahle WT.
    Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
    [Abstract] [Full Text] [Related]

  • 3. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, Stiles A.
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [Abstract] [Full Text] [Related]

  • 4. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR.
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [Abstract] [Full Text] [Related]

  • 5. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA, Cosgrove JF, MacMahon P.
    Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
    [Abstract] [Full Text] [Related]

  • 6. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
    Wang D, Cummins C, Bayliss S, Sandercock J, Burls A.
    Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
    [Abstract] [Full Text] [Related]

  • 7. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
    Roeckl-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH.
    Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
    [Abstract] [Full Text] [Related]

  • 8. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
    Marchetti A, Lau H, Magar R, Wang L, Devercelli G.
    Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740
    [Abstract] [Full Text] [Related]

  • 9. Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.
    Warren A, Langley JM, Thomas W, Scott J.
    Can J Cardiol; 2007 May 01; 23(6):463-6. PubMed ID: 17487291
    [Abstract] [Full Text] [Related]

  • 10. [Prevention of respiratory syncytial virus infection by SYNAGIS (palivizumab)].
    Pin I, Pilenko C, Bost M.
    Allerg Immunol (Paris); 2002 Dec 01; 34(10):371-4. PubMed ID: 12575622
    [Abstract] [Full Text] [Related]

  • 11. Economic evaluation of palivizumab in children with congenital heart disease: a Canadian perspective.
    Harris KC, Anis AH, Crosby MC, Cender LM, Potts JE, Human DG.
    Can J Cardiol; 2011 Dec 01; 27(4):523.e11-5. PubMed ID: 21664100
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
    Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA.
    Pediatrics; 1999 Sep 01; 104(3 Pt 1):419-27. PubMed ID: 10469764
    [Abstract] [Full Text] [Related]

  • 13. Prophylaxis with palivizumab against respiratory syncytial virus infection in infants with congenital heart disease--who should receive it?
    Sunnegårdh J.
    Acta Paediatr; 2006 Apr 01; 95(4):388-90. PubMed ID: 16720482
    [Abstract] [Full Text] [Related]

  • 14. Infection by the respiratory syncytial virus in infants and young children at high risk.
    Bonnet D, Schmaltz AA, Feltes TF.
    Cardiol Young; 2005 Jun 01; 15(3):256-65. PubMed ID: 15865827
    [Abstract] [Full Text] [Related]

  • 15. The European Forum for Clinical Management: prophylaxis against the respiratory syncytial virus in infants and young children with congenital cardiac disease.
    Tulloh RM, Feltes TF.
    Cardiol Young; 2005 Jun 01; 15(3):274-8. PubMed ID: 15865829
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
    Reeve CA, Whitehall JS, Buettner PG, Norton R, Reeve DM, Francis F.
    J Paediatr Child Health; 2006 May 01; 42(5):253-8. PubMed ID: 16712554
    [Abstract] [Full Text] [Related]

  • 17. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.
    Pediatrics; 2003 Dec 01; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [Abstract] [Full Text] [Related]

  • 18. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM.
    Arch Pediatr Adolesc Med; 2000 Jan 01; 154(1):55-61. PubMed ID: 10632251
    [Abstract] [Full Text] [Related]

  • 19. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep 01; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [Abstract] [Full Text] [Related]

  • 20. Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis.
    Numa A.
    J Paediatr Child Health; 2000 Oct 01; 36(5):422-7. PubMed ID: 11036794
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.